Peptides

Unregulated use of peptides has raised alarms among researchers. Consumer demand for experimental peptides has exploded over the last decade, driven by social media hype and a growing distrust of public health guidance.

The unregulated use of peptides has raised alarm among researchers. Over the last decade, consumer demand for experimental peptides has exploded. This rise is attributed to social media hype and a growing distrust in public health guidance.

Michigan Senate candidate Abdul El-Sayed promoted health products, including supplements like 'Moon Juice Brain Dust' and a metabolism-tracking device, while using his medical credentials, despite previously criticizing others for similar practices and claiming he would not sell health products. His podcast, which included ad reads for these items, generated a six-figure income.

An FDA advisory panel recently approved some popular peptides, drawing significant market attention and raising concerns about the unregulated supply.

An FDA advisory panel voted to approve certain peptides, increasing market attention and raising concerns about their unregulated supply.

A federal judge sentenced the owner of a peptide company to nearly six years in prison after finding the business deceived customers and sold products that were adulterated with steroids.

A US drug advisory committee has recommended approval for several experimental peptides, though no large-scale human tests have been conducted on these compounds, according to columnist Grace Wade. Peptides are being promoted as a new wellness trend, but their efficacy remains unproven due to limited testing.

An advisory committee for the Food and Drug Administration has narrowly voted to add six peptides to a drug compounding list.

An FDA advisory panel recommended allowing compounding pharmacies to manufacture the peptide epitalon but narrowly voted against emideltide. The decision brings health secretary Robert F. Kennedy, Jr. closer to expanding access to unapproved peptides, which have gained popularity through social media influencers.

BPC-157, a peptide rumored to treat various conditions, has gained popularity through influencers and Robert F. Kennedy Jr. An FDA advisory committee recommended allowing compounding pharmacies to produce it despite limited safety data. Telehealth companies may soon offer it if the FDA approves the recommendation.

Scientists have developed a device to supercool kidneys to -4°C without ice formation, enabling longer preservation for potential human transplants. The article also highlights China's efforts to replace US chips with homegrown technology and discusses other tech-related topics like space data centers and AI regulations.

The FDA's committee on compounded drugs voted to add peptides to the list of substances compounding pharmacies can make, despite opposition from agency scientists who raised concerns about the lack of demonstrated benefits.

An FDA advisory panel recommended easing restrictions on certain unapproved peptides, which are short chains of amino acids that can help regulate a variety of functions in the body. CBS News correspondent Adam Yamaguchi reported the development.

The FDA advisory committee is considering lifting a ban to expand access to seven popular peptides. Wellness influencers and Health Secretary Robert F. Kennedy Jr. have shown support for these peptides, which were discussed in a New Yorker article by Dr. Dhruv Khullar.

An FDA panel endorsed unproven peptides, with outside experts—some having vested interests—recommending their addition to the FDA's bulk list. The 'Wolverine stack' peptides were highlighted as promoted by influencers like Joe Rogan.

An FDA panel has recommended easing restrictions on several peptides. The Food and Drug Administration headquarters is located in White Oak, Md.

An FDA panel narrowly voted 8-6 to expand access to BPC-157, an unapproved peptide popular among wellness influencers like Joe Rogan, despite FDA scientists' concerns about its safety and efficacy. The panel included industry-connected experts, and the decision is part of a broader review of seven peptides for potential compounding pharmacy use.

The FDA is reviewing several peptides popularized by RFK Jr. and wellness influencers, despite limited evidence of their safety or effectiveness. The agency's advisers include industry-linked experts, while FDA scientists argue more data is needed before allowing broader access.

The FDA is evaluating whether seven peptides, including BPC-157 and TB-500, can be legally compounded, which may lead to increased availability in the U.S. The decision could determine the legal status of these peptides for broader use among Americans.

The FDA's peptide panel is expected to have a clash today. The panel will discuss peptides over two days, as noted in STAT's Morning Rounds newsletter.

Advisers to the Food and Drug Administration are considering evidence for seven different peptides. Favorable votes could lead to easier access to these peptides.

Advisers to the Food and Drug Administration are evaluating evidence for seven peptides. A favorable decision could lead to easier access to these substances.

An FDA advisory panel will discuss allowing compounding pharmacies to manufacture seven peptides currently deemed unsafe. The panel includes members with potential conflicts of interest, such as physicians who prescribe peptides and Tennessee state Sen. Bobby Harshbarger, whose mother, U.S. Rep. Diana Harshbarger, advocates for looser peptide regulations.

The FDA is reviewing peptides, a group of controversial chemicals, as federal health advisers meet to assess them. The chemicals are favored by RFK Jr. and wellness influencers.

The FDA is reviewing peptides popularized by RFK Jr. and wellness influencers like Joe Rogan and Gary Brecka, despite limited evidence of safety or effectiveness. The agency's advisory panel includes experts with financial ties to the peptide industry, raising concerns about conflicts of interest.

The FDA is reviewing peptides, unproven substances popularized by RFK Jr. and wellness influencers, with health advisers divided over their safety and efficacy. The meeting includes experts with financial ties to the peptide industry, raising concerns about conflicts of interest.

A user received a scam call claiming they had illegal goods and were involved in money laundering. The scammer used tactics like fake legal threats and impersonated RCMP and Canadian intelligence agencies. The victim refused to cooperate, reported the incident to authorities, and changed bank passwords.

The FDA is considering approval for compounding pharmacies to legally mix wellness peptides like BPC-157 and TB-500, which could create a $30 billion market. Telehealth companies like Hims & Hers, which previously profited from compounded Ozempic alternatives, are positioning to expand into peptide therapies despite limited long-term safety data.

Researchers are using AI and quantum computing to develop new peptides for drug development targeting underserved populations and rare diseases. The project combined funding and time to demonstrate quantum computing's potential in this field.

Minnesota Live is discussing trending health topics with Dr. Archelle Georgiou, who addresses GLP-1s, peptides, antidepressants, and cancer. The segment aims to provide insights through a trusted medical perspective.

Unproven peptides popular among wellness influencers are in a gray market due to Biden-era restrictions. The Trump administration could potentially lift these restrictions.

FDA career scientists have determined there is insufficient evidence to support peptides under consideration for production by compounding, countering HHS Secretary Robert F. Kennedy Jr.'s efforts to expand access to these substances.

FDA scientists have raised concerns about the lack of evidence for the efficacy and safety of peptides, which are supported by RFK Jr. An FDA panel will consider easing access to peptides later this month despite these concerns.

Peptides are widely promoted in health and beauty for benefits like weight loss and tissue repair, but many sold as 'research only' lack FDA approval. The FDA is easing access to peptides despite warnings about undermining drug approval, while experts note that only rigorously studied, FDA-approved peptides (like Tirzepatide and Semaglutide) have strong scientific backing.

The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of unapproved drugs popular with followers of Robert F. Kennedy Jr. The agency posted meeting materials online Monday.

The FDA will convene a panel to review the safety of popular peptide injections, with participants including doctors and pharmacists financially tied to the peptide industry. The meeting, part of efforts to reshape health policy under Robert F. Kennedy Jr., will assess peptides like BPC-157 and TB-500, which the FDA has previously warned are unapproved and risky.

The FDA's upcoming panel to review controversial peptide drugs includes health professionals with financial ties to the industry, including clinics and pharmacies promoting unproven peptides. The meeting follows concerns about the safety and regulatory status of substances like BPC-157 and TB-500, which are marketed for wellness purposes but lack scientific validation. Health Secretary Robert F. Kennedy Jr. has publicly supported these peptides.

The FDA announced eight new panelists to advise on regulations for compounding pharmacies manufacturing peptides. Most panelists are linked to businesses promoting peptides, and one, Bobby Harshbarger, is a pharmacist and Tennessee state senator. A professor raised concerns about the panelists' ties to unproven peptide and stem cell treatments.

The FDA will hold a meeting in July to discuss easing restrictions on research peptides, which are currently sold in a gray market with limited safety and efficacy evidence. If restrictions are relaxed, US compounding pharmacies could legally produce and fill prescriptions for these peptides.

Jenny Mollen described severe side effects, including 'blood everywhere,' from microdosing Tirzepatide, a GLP-1 drug typically used for diabetes, while taking a cocktail of peptides.